DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. It expresses Molina’s determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member’s benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member’s benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member’s plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS’s Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina Clinical Policy (MCP) document and provide the directive for all Medicare members.  

DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL

Germ cell tumors
Germ cell tumors are a type of tumor that begins in the cells that give rise to sperm or eggs. Germ cell tumors can occur almost anywhere in the body and can be either benign or malignant. These tumors are composed primarily of testicular neoplasms (seminomas or nonseminomatous tumors) but also include ovarian and extragonadal germ-cell tumors (e.g., retroperitoneal or mediastinal tumors). Germ-cell tumors are classified according to their histology, stage, prognosis, and response to chemotherapy. Histologies include seminoma, embryonal carcinoma, teratoma, choriocarcinoma, yolk sac tumor, and mixed germ-cell tumors. Seminomas are the most common; all other types are collectively referred to as nonseminomatous germ-cell tumors. Germ-cell tumors also are divided into good, intermediate, or poor-risk categories based on histology, site, and extent of primary tumor, and on serum marker levels. According to the International Germ Cell Cancer Collaborative Group (IGCCCG) consensus, risk classification of testicular germ cell tumors are separated by nonseminoma and seminoma diagnosis. There is no poor risk disease in the seminoma category. In nonseminoma, poor prognosis or poor risk disease is indicated by one of the following: mediastinal primary tumor, nonpulmonary visceral metastases, and elevation of any one post-orchiectomy marker (alpha fetal protein [AFP] greater than 10,000 ng/mL, human choriogonadotropin [hCG] greater than 50,000 IU/L, or lactate dehydrogenase [LDH] greater than 10 times the upper limit of normal).

Stem Cell Transplantation
Stem-cell transplantation refers to transplantation of hematopoietic stem cells (HSCs) from a donor into a patient. HSCs are immature cells that can develop into any of the three types of blood cells (red cells, white cells or platelets). HSCs are created in the bone marrow and are found in the bone marrow and peripheral blood. There is also a high concentration of HSCs in umbilical-cord blood. Hematopoietic stem-cell transplantation (HSCT) can be either autologous (using the person’s own stem cells) or allogeneic (using stem cells from a donor). In allogeneic HSCT, it is preferable for donors to have a human leukocyte antigen (HLA) type that is identical to the recipient. Matching is performed on the basis of variability at three of more loci of the HLA gene (e.g., HLA-A, HLA-B, HLA-DRB1). As HLA variability increases, transplant-related morbidity and mortality, including graft rejection and graft-versus-host disease, also increase.

**RECOMMENDATION**

All transplants require prior authorization from the Corporate Transplant Department. Solid organ transplant requests will be reviewed by the Corporate Senior Medical Director or qualified clinical designee. All other transplants will be by the Corporate Senior Medical Director or covering Medical Director. If the criteria are met using appropriate NCD and/or LCD guidelines, state regulations and/or MCP policies the Corporate Senior Medical Director’s designee can approve the requested transplant.

Members must meet UNOS guidelines for transplantation and the diagnosis must be made by a Specialist in the Disease and or Transplant Surgeon.

**Pre-Transplant Evaluation:**

Criteria for transplant evaluation include all of the following:

- History and physical examination
- Psychosocial evaluation and clearance:
  - No behavioral health disorder by history or psychosocial issues:
    - if history of behavioral health disorder, no severe psychosis or personality disorder
    - mood/anxiety disorder must be excluded or treated
    - member has understanding of surgical risk and post procedure compliance and follow-up required
  - Adequate family and social support
- EKG
- Chest x-ray
- Cardiac clearance in the presence of any of the following:
  - chronic smokers
  - > 50 years age
  - those with a clinical or family history of heart disease or diabetes
- Pulmonary clearance if evidence of pulmonary artery hypertension (PAH) or chronic pulmonary disease
- Neurological exam and clearance for transplant: [ONE]
  - Normal exam by H&P
  - Abnormal neurological exam with positive findings: [ONE]
    - Lumbar puncture normal cytology
- Lumbar puncture with cytological exam abnormal: CNS disease treated prior to clearance

- Performance Status: [ONE]
  - Karnofsky score 70-100%; or
  - Eastern Cooperative Oncology Group (ECOG) grade 0-2

- Lab studies:
  - Complete blood count, Kidney profile (blood urea nitrogen, creatinine), electrolytes, calcium, phosphorous, albumin, liver function tests, Coagulation profile (prothrombin time, and partial thromboplastin time)
  - Serologic screening for HIV, Epstein Barr virus (EBV), Hepatitis virus B (HBV), and Hepatitis C(HCV), cytomegalovirus (CMV), RPR and/or FTA:
    - If HIV positive all of the following are met:
      - CD4 count >200 cells/mm-3 for >6 months
      - HIV-1 RNA undetectable
      - On stable anti-retroviral therapy >3 months
      - No other complications from AIDS (e.g., opportunistic infection, including aspergillus, tuberculosis, coccidioides mycosis, resistant fungal infections, Kaposi’s sarcoma, or other neoplasm)
    - If abnormal serology need physician plan to address and/or treatment as indicated
  - UDS (urine drug screen) if patient is current or gives a history of past drug abuse

- Colonoscopy (if indicated or if patient is 50 ≥ older should have had an initial screening colonoscopy, after initial negative screening requires follow up colonoscopy every ten years) with complete workup and treatment of abnormal results as indicated

- GYN examination with Pap smear for women ≥21 to ≤ 65 years of age or indicated (not indicated in women who have had a TAH or TVH) with in the last three year with complete workup and treatment of abnormal results as indicated

Within the last 12 months:

- Dental examination or oral exam showing good dentition and oral care or no abnormality on panorex or plan for treatment of problems pre or post-transplant

- Mammogram (if indicated or ≥ age 40) with complete workup and treatment of abnormal results as indicated

- PSA if history of prostate cancer or previously elevated PSA with complete workup and treatment of abnormal results as indicated

*Participating Centers of Excellence may waive these criteria*

**Criteria for Hematopoietic Autologous Stem Cell transplantation (HSCT) Transplantation:**

1. **Hematopoietic Autologous stem-cell transplantation (HSCT)** may be considered medically necessary and may be authorized as salvage therapy for the treatment of germ cell tumors when the following criteria are met:

- All pre-transplant criteria are met; and
- **Single** autologous hematopoietic stem-cell transplantation may be considered medically necessary as a treatment of primary germ cell tumors in individuals treated with standard chemotherapy for the following: [ONE]
  - a partial or poor initial response; or
  - suboptimal remission; or
  - refractory germ cell tumors; or
  - relapsed disease

- **Tandem** (or sequential) autologous hematopoietic stem-cell transplantation may be considered medically necessary for the treatment of primary testicular cancer in individuals treated with standard chemotherapy for the following: [ONE]
  - a partial response; or
  - refractory germ cell tumors; or
  - relapsed disease

- **Repeat** autologous hematopoietic stem cell transplantation may be considered medically necessary for the treatment of: [ONE]
  - primary graft failure; or
  - failure to engraft

**AND**

- The requesting transplant recipient should not have any of the following **absolute contraindications**:
  - Cardiac, pulmonary, and nervous system disease that cannot be corrected and is a prohibitive risk for surgery
  - Malignant neoplasm with a high risk for reoccurrence, non-curable malignancy (excluding localized skin cancer)
  - Systemic and/or uncontrolled infection
  - AIDS (CD4 count < 200 cells/mm³)
  - Unwilling or unable to follow post-transplant regimen
    - Documented history of non-compliance
    - Inability to follow through with medication adherence or office follow-up
  - Chronic illness with one year or less life expectancy
  - Limited, irreversible rehabilitation potential
  - Active untreated substance abuse issues, requires documentation supporting free from addiction for minimally 6 months if previous addiction was present
  - No adequate social/family support

- The requesting transplant recipient should be evaluated carefully and potentially treated if the following **relative contraindications** are present:
  - Irreversible lung disease patients require consultation and clearance by a Pulmonologist prior to consideration of transplantation, this includes the following:
    - Smoking, documentation supporting free from smoking for 6 months
    - Active peptic ulcer disease
    - Active gastroesophageal reflux disease
o CVA with long term impairment that is not amendable to rehabilitation or a patient with CVA/transient ischemic attack within past 6 months
o Obesity with body mass index of >30 kg/m² may increase surgical risk
o Chronic liver disease such as Hepatitis B/C/D, or cirrhosis which increases the risk of death from sepsis and hepatic failure requires consultation by a gastroenterologist or hepatologist
o Gall bladder disease requires ultrasound of the gall bladder with treatment prior to transplantation

**CONTINUATION OF THERAPY**

When extension of a previously approved transplant authorization is requested, review using updated clinical information is appropriate.

- If Molina Healthcare has authorized prior requests for transplantation, the following information is required for medical review: [ALL]
  - Presence of no absolute contraindication as listed above;
  - History and physical within the last 12 months;
  - Kidney profile within the last 12 months;
  - Cardiac update if history of cardiac disease within two years (≥ 50 years of age);
  - Psychosocial evaluation or update within the last 12 months;
  - Per initial and updated history and physical, any other clinically indicated tests and/or scans as determined by transplant center physician or Molina Medical Director.

- If authorized prior requests for transplantation were obtained from another insurer, the following information is required for medical review: [ALL]
  - Authorization letter/documentation from previous insurer;
  - Presence of no absolute contraindication as listed above;
  - History and physical within the last 12 months;
  - Cardiac update if history of cardiac disease within two years (≥ 50 years of age);
  - Psychosocial evaluation or update within the last 12 months;

Per initial and updated history and physical, any other clinically indicated tests and/or scans as determined by transplant center physician or Molina Medical Director.

**COVERAGE EXCLUSIONS**

1. Autologous stem cell transplantation when the above criteria are not met.
2. A single autologous hematopoietic stem-cell transplantation is considered investigational for first-line treatment of poor prognosis germ-cell tumors.
3. Allogeneic HSCT is considered investigational to treat germ-cell tumors as therapy after a previously failed autologous hematopoietic stem-cell transplantation.
4. A second or repeat autologous hematopoietic transplant due to persistent, progressive or relapsed disease is considered investigational.
5. Tandem (or sequential) autologous hematopoietic stem-cell transplantation is considered investigational to treat all other germ-cell tumors of any stage.
6. Hematopoietic stem cell collection, storage and freezing for a future unplanned transplant is not covered
SUMMARY OF MEDICAL EVIDENCE

First Line Therapy with auHSCT: Randomized trials have been published regarding high dose chemotherapy (HDC) with autologous HSCT as a front-line treatment for patients with poor-risk testicular cancer; however these trials have not demonstrated improved complete response rates or overall survival (OS) when used as initial therapy compared with standard dose chemotherapy. The standard of care for these individuals is conventional-dose chemotherapy. 8-10

Single auHSCT:
Seftel et al. (2011) conducted a multicenter cohort study of consecutive patients undergoing a single autologous HSCT for germ-cell tumor between January 1986 and December 2004. Of 71 subjects, median follow-up was 10.1 years. The median age was 31 years (range 16–58 years). A total of 67 of the patients had nonseminomatous germ-cell tumors and 4 had seminomatous germ-cell tumors. A total of 57 patients had primary gonadal disease and 14 had primary extragonadal disease. Of the latter, 11 patients presented with primary mediastinal disease, 2 presented with primary central nervous system (CNS) disease, and 1 presented with retroperitoneal disease. In all, 28 patients underwent autologous HSCT for relapsed disease after achieving an initial CR. Of these, 24 patients underwent autologous HSCT after a first relapse, whereas 4 patients underwent transplant after a second relapse. An additional 36 patients achieved only an incomplete response after initial therapy and proceeded to autologous HSCT after salvage chemotherapy for active residual disease. OS at 5 years was 44.7% (95% CI: 32% to 56.5%) and EFS, 43.5% (95% CI: 31.4% to 55.1%). There were 7 (10%) treatment-related deaths within 100 days of transplant. Three (4.2%) patients developed secondary malignancies. Of 33 relapses, 31 occurred within 2 years of the transplant. Two very late relapses occurred 13 and 11 years after transplant. In a multivariate analysis, a favorable outcome was associated with International Germ Cell Consensus Classification (IGCCC) good prognosis disease at diagnosis, primary gonadal disease, and response to salvage chemotherapy. 21

Agarwal et al. (2009) reported their experience at Stanford in treating 37 consecutive patients who received HDC and autologous HSCT between 1995 and 2005 for relapsed germ-cell tumors. The median patient age was 28 years (range, 9-59 years), with 34 males and three females. Primary tumor sites included 24 testes/adnexal, 10 chest/neck/retroperitoneal, and 3 CNS. Twenty-nine of the patients had received prior standard salvage chemotherapy. Three-year OS was 57% (95% CI: 41% to 71%), and 3-year PFS was 49% (95% CI: 33% to 64%). 23

Summary: Improved overall- and disease-free survival rates have been demonstrated in one randomized controlled study and several prospective and retrospective studies. Durable complete remissions may be achieved with salvage therapy including HDC followed by autologous HSCT in a small subset of individuals. 12 13 21 23 24

Tandem auHSCT:
Lotz et al. (2005) reported the results of a Phase II study on 3 consecutive cycles of high-dose chemotherapy regimens supported by autologous HSCT in 45 poor-prognosis patients with relapsed germ-cell tumors.15
From March 1998 to September 2001 (median follow-up, 31.8 months), 45 patients (median age, 28 years) were enrolled. Most of the patients (76%) had testicular primaries; 13% had mediastinal primaries; 11% retroperitoneal, hepatic or unknown. Of all patients, 22 received the complete course. Twenty-five patients died from progression and five from toxicity. The overall response rate was 37.7%, including an 8.9% complete response rate. The median OS was 11.8 months. The 3-year survival and PFS rate was 23.5%. The authors used the “Beyer” prognostic score to predict the outcome of high-dose chemotherapy and concluded that patients with a Beyer score greater than 2 did not benefit from this approach, confirming that highly refractory patients and particularly patients with resistant/refractory primary mediastinal germ cell tumors do not benefit from high-dose chemotherapy. The authors indicate that better selection criteria have to be fulfilled in forthcoming studies.

Lorch et al. (2007 & 2012) compared single- versus sequential HDC with autologous HSCT as first or subsequent salvage treatment in patients with relapsed or refractory germ-cell tumors. This represented the first salvage therapy received in 86% of the patients in arm A and 85% in arm B, whereas 14% (arm A) and 15% (arm B) had received one or more previous salvage regimens prior to randomization. With a median follow-up time of 36 months, 109 (52%) of 211 patients were alive, and 91 (43%) of 211 patients were progression free. At 1 year, event-free, progression-free, and overall survival rates were 40%, 53%, and 80%, respectively, in arm A compared with 37%, 49%, and 61%, respectively, in arm B (p >0.05 for all comparisons). Long-term results were reported in 2012 from this study indicated five-year PFS as 47% (95% CI, 37%-56%) in arm A and 45% (95% CI, 35%-55%) in arm B (hazard ratio, 1.16; 95% CI, 0.79-1.70; p=.454). Five-year OS was 49% (95% CI, 40%-59%) in arm A and 39% (95% CI, 30%-49%) in arm B (hazard ratio, 1.42; 95% CI, 0.99-2.05; p=.057).

Results showed that patients with relapsed or refractory germ-cell tumors can achieve durable long-term survival after single as well as sequential HSCT and that fewer early deaths related to toxicity translated into superior long-term OS after sequential HSCT.

Lazarus et al. (2007) reported the results of autologous HSCT in relapsed testicular/germ-cell cancer from registry data from the Center for International Blood and Marrow Transplant Research. Patients with mediastinal primaries were excluded. Data included 300 patients from 76 transplant centers in 8 countries who received either a single transplant or tandem autologous HSCT between 1989 and 2001. Of the 300 patients, 102 received tandem, and 198 single planned autologous HSCT. PFS and OS at 1, 3, and 5 years was similar for both groups. The probability of PFS at 5 years for the tandem transplant group was 34% (95% CI: 25–44%) versus 38% (95% CI: 31–45%) in the single transplant group; p=0.50. The probability of 5-year OS was 35% (95% CI: 25–46%) versus 42% (95% CI: 35–49%), respectively; p=0.29.

Summary: The role of tandem or sequential autologous transplants in relapsed testicular germ cell tumors has been assessed in one Phase II study, one randomized study, several retrospective series and a comparative effectiveness review from the Agency for Healthcare Research and Quality. Tandem or sequential HSCT may provide survival benefit, and the randomized study showed lower treatment-related mortality with sequential HSCT compared with single HSCT.

Professional Organizations
The NCCN Clinical Practice Guidelines in Oncology for Testicular Cancer (2017) assigns a 2A recommendation to the second-line chemotherapy regimen consisting of paclitaxel, ifosfamide, carboplatin, and etoposide administered with peripheral blood stem cell support at 14-21 day intervals for three cycles.

In the Clinical Practice Guidelines in Oncology for Ovarian Cancer (2017) indicates that high-dose chemotherapy with stem cell support is an acceptable therapy for those with residual or recurrent malignant germ-cell tumors.

**CODING INFORMATION:** THE CODES LISTED IN THIS POLICY ARE FOR REFERENCE PURPOSES ONLY. LISTING OF A SERVICE OR DEVICE CODE IN THIS POLICY DOES NOT IMPLY THAT THE SERVICE DESCRIBED BY THIS CODE IS A COVERED OR NON-COVERED. COVERAGE IS DETERMINED BY THE BENEFIT DOCUMENT. THIS LIST OF CODES MAY NOT BE ALL INCLUSIVE.

### CPT Description

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>38205</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic</td>
</tr>
<tr>
<td>38206</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous</td>
</tr>
<tr>
<td>38230</td>
<td>Bone marrow harvesting for transplantation; allogeneic</td>
</tr>
<tr>
<td>38232</td>
<td>Bone marrow harvesting for transplantation; autologous</td>
</tr>
</tbody>
</table>

#### Collection Codes

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>38207</td>
<td>Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage</td>
</tr>
<tr>
<td>38208</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, without washing</td>
</tr>
<tr>
<td>38209</td>
<td>Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing</td>
</tr>
<tr>
<td>38210</td>
<td>Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion</td>
</tr>
<tr>
<td>38211</td>
<td>Transplant preparation of hematopoietic progenitor cells; tumor cell depletion</td>
</tr>
<tr>
<td>38212</td>
<td>Transplant preparation of hematopoietic progenitor cells; red blood cell removal</td>
</tr>
<tr>
<td>38213</td>
<td>Transplant preparation of hematopoietic progenitor cells; platelet depletion</td>
</tr>
<tr>
<td>38214</td>
<td>Transplant preparation of hematopoietic progenitor cells; plasma (volume) depletion</td>
</tr>
<tr>
<td>38215</td>
<td>Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer</td>
</tr>
</tbody>
</table>

#### Cell Processing Services

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>38240</td>
<td>Bone marrow or blood-derived peripheral stem cell transplantation; allogeneic</td>
</tr>
<tr>
<td>38241</td>
<td>Bone marrow or blood-derived peripheral stem cell transplantation; autologous</td>
</tr>
<tr>
<td>38242</td>
<td>Bone marrow or blood-derived peripheral stem cell transplantation; allogeneic donor lymphocyte infusions</td>
</tr>
<tr>
<td>38243</td>
<td>Bone marrow or blood-derived peripheral stem cell transplantation; allogeneic hematopoietic cellular transplant boost</td>
</tr>
</tbody>
</table>

### HCPCS Description

<table>
<thead>
<tr>
<th>HCPCS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2140</td>
<td>Cord blood harvesting for transplantation, allogeneic</td>
</tr>
<tr>
<td>S2142</td>
<td>Cord blood derived stem-cell transplantation, allogeneic</td>
</tr>
<tr>
<td>S2150</td>
<td>Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous,</td>
</tr>
</tbody>
</table>
harvesting, transplantation, and related complications; including pheresis and cell preparation/storage; marrow ablative therapy; drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition

<table>
<thead>
<tr>
<th>ICD-9</th>
<th>Description: [For dates of service prior to 10/01/2015]</th>
</tr>
</thead>
<tbody>
<tr>
<td>158.0</td>
<td>Malignant neoplasm of retroperitoneum</td>
</tr>
<tr>
<td>164.2</td>
<td>Malignant neoplasm of anterior mediastinum</td>
</tr>
<tr>
<td>164.3</td>
<td>Malignant neoplasm of posterior mediastinum</td>
</tr>
<tr>
<td>183.0</td>
<td>Malignant neoplasm of ovary</td>
</tr>
<tr>
<td>186-186.9</td>
<td>Malignant neoplasm of testis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>Description: [For dates of service on or after 10/01/2015]</th>
</tr>
</thead>
<tbody>
<tr>
<td>C48.0</td>
<td>Malignant neoplasm of retroperitoneum</td>
</tr>
<tr>
<td>C56-C56.9</td>
<td>Malignant neoplasm of ovary</td>
</tr>
<tr>
<td>C62-C62.92</td>
<td>Malignant neoplasm of testis</td>
</tr>
</tbody>
</table>

**RESOURCE REFERENCES**

**Government Agency**

**Professional Society Guidelines**
4. National Cancer Institute:

**Peer Reviewed Publications**

Other Resources

29. UpToDate: Rose, BD (Ed), UpToDate, Waltham, MA. 2017.
   • Oh W. Overview of the treatment of testicular germ cell tumors.
   • Cutler C. The approach to hematopoietic cell transplantation survivorship.
   • Holmberg L, Deeg H et al. Determining eligibility for autologous hematopoietic cell transplantation.
31. Peer Review: Policy reviewed by AMR practicing physician board certified in Internal Medicine, Oncology, Hematology. 10/27/17

Revision History: 6/2/15: Updated pre-transplant criteria, continuation of therapy, absolute and relative contraindications and coding sections. 12/17: The favorable and unfavorable prognostic factors were removed for single auto transplant. Tandem transplant criteria was updated and repeat transplant criteria was added. The professional guidelines and reference sections were updated.